Cargando…

The canine chronic atrioventricular block model in cardiovascular preclinical drug research

Ventricular cardiac arrhythmia is a life threating condition arising from abnormal functioning of many factors in concert. Animal models mirroring human electrophysiology are essential to predict and understand the rare pro‐ and anti‐arrhythmic effects of drugs. This is very well accomplished by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Loen, Vera, Vos, Marc A., van der Heyden, Marcel A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291585/
https://www.ncbi.nlm.nih.gov/pubmed/33684961
http://dx.doi.org/10.1111/bph.15436
_version_ 1784749170500829184
author Loen, Vera
Vos, Marc A.
van der Heyden, Marcel A. G.
author_facet Loen, Vera
Vos, Marc A.
van der Heyden, Marcel A. G.
author_sort Loen, Vera
collection PubMed
description Ventricular cardiac arrhythmia is a life threating condition arising from abnormal functioning of many factors in concert. Animal models mirroring human electrophysiology are essential to predict and understand the rare pro‐ and anti‐arrhythmic effects of drugs. This is very well accomplished by the canine chronic atrioventricular block (CAVB) model. Here we summarize canine models for cardiovascular research, and describe the development of the CAVB model from its beginning. Understanding of the structural, contractile and electrical remodelling processes following atrioventricular (AV) block provides insight in the many factors contributing to drug‐induced arrhythmia. We also review all safety pharmacology studies, efficacy and mechanistic studies on anti‐arrhythmic drugs in CAVB dogs. Finally, we compare pros and cons with other in vivo preclinical animal models. In view of the tremendous amount of data obtained over the last 100 years from the CAVB dog model, it can be considered as man's best friend in preclinical drug research. LINKED ARTICLES: This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc
format Online
Article
Text
id pubmed-9291585
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92915852022-07-20 The canine chronic atrioventricular block model in cardiovascular preclinical drug research Loen, Vera Vos, Marc A. van der Heyden, Marcel A. G. Br J Pharmacol Preclinical Models for Cardiovascular Disease Research (Bjp 75th Anniversary) ‐ Themed Issue Reviews Ventricular cardiac arrhythmia is a life threating condition arising from abnormal functioning of many factors in concert. Animal models mirroring human electrophysiology are essential to predict and understand the rare pro‐ and anti‐arrhythmic effects of drugs. This is very well accomplished by the canine chronic atrioventricular block (CAVB) model. Here we summarize canine models for cardiovascular research, and describe the development of the CAVB model from its beginning. Understanding of the structural, contractile and electrical remodelling processes following atrioventricular (AV) block provides insight in the many factors contributing to drug‐induced arrhythmia. We also review all safety pharmacology studies, efficacy and mechanistic studies on anti‐arrhythmic drugs in CAVB dogs. Finally, we compare pros and cons with other in vivo preclinical animal models. In view of the tremendous amount of data obtained over the last 100 years from the CAVB dog model, it can be considered as man's best friend in preclinical drug research. LINKED ARTICLES: This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc John Wiley and Sons Inc. 2021-05-04 2022-03 /pmc/articles/PMC9291585/ /pubmed/33684961 http://dx.doi.org/10.1111/bph.15436 Text en © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Preclinical Models for Cardiovascular Disease Research (Bjp 75th Anniversary) ‐ Themed Issue Reviews
Loen, Vera
Vos, Marc A.
van der Heyden, Marcel A. G.
The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title_full The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title_fullStr The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title_full_unstemmed The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title_short The canine chronic atrioventricular block model in cardiovascular preclinical drug research
title_sort canine chronic atrioventricular block model in cardiovascular preclinical drug research
topic Preclinical Models for Cardiovascular Disease Research (Bjp 75th Anniversary) ‐ Themed Issue Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291585/
https://www.ncbi.nlm.nih.gov/pubmed/33684961
http://dx.doi.org/10.1111/bph.15436
work_keys_str_mv AT loenvera thecaninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch
AT vosmarca thecaninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch
AT vanderheydenmarcelag thecaninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch
AT loenvera caninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch
AT vosmarca caninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch
AT vanderheydenmarcelag caninechronicatrioventricularblockmodelincardiovascularpreclinicaldrugresearch